{"disease":{"id":"advanced-biliary-tract-cancer","name":"advanced biliary tract cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06360354","title":"A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04969887","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Olivia Newton-John Cancer Research Institute","has_results":false},{"nct_id":"NCT07197554","title":"A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":171,"lead_sponsor_name":"SEED Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07021066","title":"Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT07326137","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","phase":"","overall_status":"RECRUITING","enrollment_count":103,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04733521","title":"A Phase 1/2 Study of SC-43 in Combination With Cisplatin","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"RaND Biosciences","has_results":false},{"nct_id":"NCT06988592","title":"GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05733000","title":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT07351591","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":88,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT05253053","title":"To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"TransThera Sciences (Nanjing), Inc.","has_results":false},{"nct_id":"NCT05564403","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06789848","title":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06893380","title":"Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":61,"lead_sponsor_name":"CHA University","has_results":false},{"nct_id":"NCT05742750","title":"A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04005339","title":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Georgetown University","has_results":false},{"nct_id":"NCT04172402","title":"NGS as the First-line Treatment in Advanced Biliary Tract Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT05749900","title":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04727996","title":"Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05410197","title":"Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":43,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04492033","title":"A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Handok Inc.","has_results":false},{"nct_id":"NCT05116891","title":"A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Cantargia AB","has_results":false},{"nct_id":"NCT04722133","title":"Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT05527821","title":"Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04217954","title":"HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05820906","title":"Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04027764","title":"Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Dai, Guanghai","has_results":false},{"nct_id":"NCT05823987","title":"Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05781074","title":"Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03082053","title":"A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"ASLAN Pharmaceuticals","has_results":false},{"nct_id":"NCT05653180","title":"IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT05812430","title":"Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT05009953","title":"Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"CSPC Ouyi Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03358849","title":"Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell (\"SMT-NK\") Cell Therapy in Advanced Biliary Tract Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT02597465","title":"A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Sun Pharma Advanced Research Company Limited","has_results":false},{"nct_id":"NCT04578444","title":"An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}